KBC Securities - Amoeba SA (AMEBA) Amoéba Capital increase via a private placement (11.4% at € 0.75)

Report

KBC Securities

Guy Sips

Amoéba Capital increase via a private placement (11.4% at € 0.75)

Amoéba closed a capital increase via a private placement, carried out through an accelerated book-building process. They placed 8,897,973 new shares at a price of €0.75 per share for a total amount of €6,673,480, representing 11.43% of its share capital following the transaction. As a result (based on the higher number of share and taking into account the cash inflow) we lower our Target Price to € 1.4 but maintain our Buy rating.

26/03/2026 1 EN

Underlying

Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

See profile

FR0011051598 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Amoéba Announcing its first order from its partner Koppert

We welcome Amoéba announced its first order from its partner Koppert. As a result Amoéba delivered on its promise to become a commercial company. Recall that Amoéba's biocontrol activities are now structured around its subsidiary Green 4 Agro. Amoéba stressed that this first order is proof of the promising nature of its partnership with Koppert. We reiterate our Buy rating and € 1.5 Target Price.

March 12, 2026 March 12, 2026 1 EN

KBC Securities

Amoéba Transforming into an industrial and commercial company by end FY26

Amoéba stated that in FY25, major regulatory and commercial milestones have laid the groundwork for commercialisation in FY26. We maintain our positive stance (Buy, € 1.5 TP) as after FY25 marked by intense regulatory and pre-commercial activity (both in biocontrol and cosmetics, as well as recognition from agricultural and wine-growing professionals), FY26 could be a turning point for Amoéba, marking its transformation into an industrial and commercial company. This change is based on the latest regulatory advances, as the ANSES (French Agency for Food, Environmental and Occupational Health &...

February 24, 2026 February 24, 2026 1 EN

Tessenderlo Feedback FY25 results conference call

Below are the highlights of the FY25 results conference call. Tessenderlo's FY25 adjusted EBITDA increased by 8.5% to 288.1m, which was 3% below our forecast and 6% below consensus. FY26 guidance calls for adjusted EBITDA in line with 2025 which is also below our and consensus forecasts. Despite the difficult macro economic environment, we remind that the company is generating sizeable FCF which was until recently used to regularly buy back own shares. We consider valuation to be attractive enough from maintaining our Accumulate rating with target price maintained at € 28.

2h / 40m 2h / 40m 1 EN

Jacob Mekhael

Jacob Mekhael

Hyloris FY25 results hold no major surprises

Hyloris reported FY25 results with a cash position of € 13.8m (YE24: € 23.6m), and revenue of € 7.2m (FY24: € 8.5m), driven by increased royalties but offset by lower milestone payments. Hyloris is yet to receive income related to commercialisation of Maxigesic IV in the US as the launch has been paused and restarted. The company did not provide specific cash runway guidance, but believes it has funding for development and strategic growth. € 6 TP and Hold maintained.

9h / 56m 9h / 56m 1 EN

Wim Hoste

Wim Hoste

Tessenderlo FIRST LOOK: FY25 EBITDA and FY26 guidance slight miss

Tessenderlo's FY25 adjusted EBITDA increased by 8.5% to 288.1m, which was 3% below our forecast and 6% below consensus. FY26 guidance calls for adjusted EBITDA in line with 2025 which is also below our and consensus forecasts. Despite the difficult macro economic environment, we remind that the company is using its solid balance sheet and FCF to regularly buy back own shares. We consider valuation to be attractive enough from maintaining our Accumulate rating with target price maintained at € 28.

9h / 59m 9h / 59m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Amoéba Capital increase via a private placement (11.4% at € 0.75)

We are a financial services provider for several types of professional clients, each with distinct needs.

Amoéba Announcing its first order from its partner Koppert

Amoéba Transforming into an industrial and commercial company by end FY26

Tessenderlo Feedback FY25 results conference call

Hyloris FY25 results hold no major surprises

Tessenderlo FIRST LOOK: FY25 EBITDA and FY26 guidance slight miss

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe